Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab rollover study for continued access and safety follow-up
NL-OMON51829Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of spartalizumab in Non-hematologic malignancy and cancer (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of spartalizumab. Started Aug 2022; status: completed.
02
Drugs
spartalizumab
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on NL-OMON51829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51829.